Clinical Trials
53 trialsDendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeOne Medicines
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
BeOne Medicines
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Oncternal Therapeutics, Inc
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Stanford University
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
University of Nebraska
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Massachusetts General Hospital
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara Biotherapeutics
PDX+Romi
Columbia University
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics, Inc.
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
Gilead Sciences
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
AbbVie
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
A Phase I/II Study of Intratumoral Injection of SD-101
Stanford University
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Mayo Clinic
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Gilead Sciences
R2CHOP-1
Lymphoma Study Association
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
Masonic Cancer Center, University of Minnesota
Bu Flu TBI
OHSU Knight Cancer Institute
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Roswell Park Cancer Institute
LCCC0510
UNC Lineberger Comprehensive Cancer Center
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
Memorial Sloan Kettering Cancer Center
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
PCYC-0403
Pharmacyclics LLC.
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
University of Rochester
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
University of Kentucky
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Asan Medical Center
Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma
Northwestern University
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
Northwestern University
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
Fred Hutchinson Cancer Center
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Fred Hutchinson Cancer Center
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
Garden State Cancer Center at the Center for Molecular Medicine and Immunology